Both DAA and IFN arms showed that the HCC incidence decreased after three years from EOT (early vs. late HCC annual incidence: DAA 1.43% vs. 1.00% per year, IFN: 0.47% vs. 0.36% per year, both p value < 0.05 by Fine-Gray model, Supplementary Figure S4). The gene discussed is IFNA1; the disease is hepatocellular carcinoma.